New Delhi: Drug firm Lupine on Friday said it has launched its first biosimilar product in Canada. The company has introduced Rimty through its partner Sandoz Canada, the Mumbai-based drugmaker said in a statement.

Rimti is indicated for the treatment of moderate to severe active rheumatoid arthritis, Arthritis in children of unknown causeActive and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents.

Rimti is accepted for all medical indications Regarding the reference product Enbrel, Lupine said.

“With this important milestone, we continue to advance health care access and affordability for patients in Canada,” said Vineeta Gupta, CEO of Lupine.